Full Download Treatment of anemia and neutropenia in patients with chronic hepatitis C infection treated with peginterferon-ribavirin based regimens with or without protease inhibitors : a review of the clinical evidence - Canadian Agency for Drugs and Technologies in Health. | PDF Online

Download Treatment of anemia and neutropenia in patients with chronic hepatitis C infection treated with peginterferon-ribavirin based regimens with or without protease inhibitors : a review of the clinical evidence - Canadian Agency for Drugs and Technologies in Health. | PDF

[Ottawa, Ont.] : Canadian Agency for Drugs and Technologies in Health, 2012 Genre/Form: Electronic books Material Type: Document, Internet resource Document Type: Internet Resource, Computer File All Authors / Contributors: Canadian Agency for Drugs and Technologies in Health. OCLC Number: 793583321 Notes: 8 March 2012. Description: 1 online resource (19 pages) : tables, digital file. Series Title: Rapid response report. Responsibility: [prepared by Canadian Agency for Drugs and Technologies in Health]. More information: Cover image Medium cover image Thumbnail cover image Abstract: Anemia and neutropenia are key adverse effects of combination therapy with peginterferon and ribavirin (PR) for chronic hepatitis C (CHC) infection. The main strategies used to manage these adverse effects include dose reduction of either peginterferon (neutropenia) or ribavirin (anemia) or addition of other drugs that can address these adverse effects. Granulocyte colony stimulating factors (G-CSFs) like filgrastim are used to treat or prevent neutropenia while erythropoietin (EPO) is used for anemia. There are limitations to each approach. Dose reduction is a less costly option, at least in the immediate term, and is less likely to elicit adverse effects.

Title : Treatment of anemia and neutropenia in patients with chronic hepatitis C infection treated with peginterferon-ribavirin based regimens with or without protease inhibitors : a review of the clinical evidence
Author : Canadian Agency for Drugs and Technologies in Health.
Language : en
Rating :
4.90 out of 5 stars
Type : PDF, ePub, Kindle
Uploaded : Apr 12, 2021

Post Your Comments: